Shares of Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) saw unusually-strong trading volume on Monday . Approximately 9,613,900 shares traded hands during trading, an increase of 2,682% from the previous session’s volume of 345,632 shares.The stock last traded at $0.63 and had previously closed at $0.41.

Separately, Maxim Group lowered their target price on Matinas BioPharma from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Tuesday, July 10th.

Matinas BioPharma (NYSEAMERICAN:MTNB) last issued its quarterly earnings results on Friday, August 10th. The company reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.04). The company had revenue of $0.09 million during the quarter. Matinas BioPharma had a negative return on equity of 195.09% and a negative net margin of 7,558.92%.

An institutional investor recently raised its position in Matinas BioPharma stock. Paloma Partners Management Co increased its stake in Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) by 1,724.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 317,499 shares of the company’s stock after buying an additional 300,099 shares during the quarter. Paloma Partners Management Co owned about 0.34% of Matinas BioPharma worth $138,000 as of its most recent SEC filing.

Matinas BioPharma Company Profile (NYSEAMERICAN:MTNB)

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.

Read More: Terms to Better Understand Call Options

Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with's FREE daily email newsletter.